The clinic issued a public statement on how it handles tirzepatide and other weight drugs, starting with a no take-home rule.
Recap by typeshit. Post by Facebook on Facebook.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
She says the cause is a calorie surplus: some patients still manage high calorie foods and aren't exercising enough while on the drugs.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
The platform will become a subscription feature in the Health Lives Here app, with revenue shared between the companies. It's a company press release.
A market update credits new generics and steady prices for the rise in sales value, with Eli Lilly's tirzepatide featured in the numbers.
Loading…